Daniela Piani Meier

859 total citations
38 papers, 646 citations indexed

About

Daniela Piani Meier is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Hematology. According to data from OpenAlex, Daniela Piani Meier has authored 38 papers receiving a total of 646 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pathology and Forensic Medicine, 9 papers in Molecular Biology and 7 papers in Hematology. Recurrent topics in Daniela Piani Meier's work include Multiple Sclerosis Research Studies (22 papers), Sphingolipid Metabolism and Signaling (8 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Daniela Piani Meier is often cited by papers focused on Multiple Sclerosis Research Studies (22 papers), Sphingolipid Metabolism and Signaling (8 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Daniela Piani Meier collaborates with scholars based in Switzerland, United States and Germany. Daniela Piani Meier's co-authors include Davorka Tomic, Ludwig Kappos, Till Sprenger, Nicola De Stefano, Maria Pia Sormani, Dieter A. Häring, Ernst-Wilhelm Radüe, Bruce Cree, Mark S. Freedman and Terry J. Smith and has published in prestigious journals such as PLoS ONE, Neurology and Anesthesiology.

In The Last Decade

Daniela Piani Meier

38 papers receiving 628 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniela Piani Meier Switzerland 12 379 138 115 107 104 38 646
Junko Ishizeki Japan 10 148 0.4× 81 0.6× 241 2.1× 84 0.8× 67 0.6× 14 748
Volkmar Heidecke Germany 22 382 1.0× 288 2.1× 156 1.4× 86 0.8× 36 0.3× 42 1.3k
Kedar Mahajan United States 12 237 0.6× 98 0.7× 113 1.0× 57 0.5× 43 0.4× 24 557
J. Figols Spain 17 63 0.2× 481 3.5× 123 1.1× 91 0.9× 49 0.5× 58 849
Guive Sharifi Iran 15 48 0.1× 111 0.8× 168 1.5× 54 0.5× 26 0.3× 122 747
Uma Kundu United States 10 308 0.8× 182 1.3× 114 1.0× 50 0.5× 44 0.4× 17 590
Ayala Pollack Israel 27 43 0.1× 95 0.7× 364 3.2× 43 0.4× 31 0.3× 88 1.9k
Yongqiang Dai China 20 649 1.7× 455 3.3× 195 1.7× 65 0.6× 208 2.0× 45 1.1k
Renata Simm Brazil 11 717 1.9× 672 4.9× 66 0.6× 14 0.1× 311 3.0× 27 977
Rana Zabad United States 16 333 0.9× 166 1.2× 137 1.2× 57 0.5× 75 0.7× 34 722

Countries citing papers authored by Daniela Piani Meier

Since Specialization
Citations

This map shows the geographic impact of Daniela Piani Meier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniela Piani Meier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniela Piani Meier more than expected).

Fields of papers citing papers by Daniela Piani Meier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniela Piani Meier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniela Piani Meier. The network helps show where Daniela Piani Meier may publish in the future.

Co-authorship network of co-authors of Daniela Piani Meier

This figure shows the co-authorship network connecting the top 25 collaborators of Daniela Piani Meier. A scholar is included among the top collaborators of Daniela Piani Meier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniela Piani Meier. Daniela Piani Meier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Montalbán, Xavier, Jerry S. Wolinsky, Douglas L. Arnold, et al.. (2023). Update on Long-Term Efficacy and Safety of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, Over 5 Years from an Ongoing Phase 2 Open-Label Extension. Multiple Sclerosis and Related Disorders. 80. 105329–105329. 2 indexed citations
2.
Rivera, Samantha Cruz, Olalekan Lee Aiyegbusi, Daniela Piani Meier, et al.. (2023). The effect of disease modifying therapies on fatigue in multiple sclerosis. Multiple Sclerosis and Related Disorders. 79. 105065–105065. 5 indexed citations
3.
Kunz, Laura, Witold Wolski, Daniela Piani Meier, et al.. (2022). Proteomic profiling of canine fibrosarcoma and adjacent peritumoral tissue. Neoplasia. 35. 100858–100858. 6 indexed citations
4.
Fox, Robert J., Douglas L. Arnold, Gavin Giovannoni, et al.. (2020). Siponimod Reduces Grey Matter Atrophy in Patients with Secondary Progressive Multiple Sclerosis: Subgroup Analyses from the EXPAND Study (1130). Neurology. 94(15_supplement). 6 indexed citations
5.
Kappos, Ludwig, Gavin Giovannoni, Ralf Gold, et al.. (2020). Long-term Efficacy and Safety of Siponimod in Patients with SPMS: EXPAND Extension Analysis Up to 5 Years (4128). Neurology. 94(15_supplement). 2 indexed citations
6.
Arnold, Douglas L., Bruce Cree, Amit Bar‐Or, et al.. (2020). Magnetization Transfer Imaging in Secondary Progressive Multiple Sclerosis Patients Treated with Siponimod: Results from the Phase 3 EXPAND Study (4037). Neurology. 94(15_supplement). 1 indexed citations
7.
Kappos, Ludwig, Patrick Vermersch, Bruce Cree, et al.. (2019). A Novel Functional Composite Endpoint to Characterize Disease Progression in Patients with Secondary Progressive Multiple Sclerosis (S12.006). Neurology. 92(15_supplement). 8 indexed citations
8.
9.
Meier, Daniela Piani, et al.. (2017). Multiple Sclerosis Care Optimization Tool (MS-COT): A Clinical application prototype to predict future disease activity (P1.368). Neurology. 88(16_supplement). 1 indexed citations
10.
Ritter, Shannon, et al.. (2017). Efficacy and safety outcomes in vitamin D supplement users in the fingolimod phase 3 trials. Journal of Neurology. 265(2). 348–355. 11 indexed citations
11.
12.
Graf, Ricarda, Gianluca Boo, M. Hässig, et al.. (2016). Swiss Feline Cancer Registry 1965–2008: the Influence of Sex, Breed and Age on Tumour Types and Tumour Locations. Journal of Comparative Pathology. 154(2-3). 195–210. 47 indexed citations
13.
14.
Montalbán, Xavier, Jeffrey A. Cohen, Frederik Barkhof, et al.. (2015). Effect of fingolimod versus interferon-beta1a on no evidence of disease activity or worsening (NEDA-4) in the TRANSFORMS study (P4.001). Neurology. 84(14_supplement). 5 indexed citations
15.
Jeffery, Douglas, Elisabetta Verdun di Cantogno, Shannon Ritter, et al.. (2015). The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS. Journal of Neurology. 263(2). 299–305. 12 indexed citations
16.
Sormani, Maria Pia, Ludwig Kappos, Till Sprenger, et al.. (2015). Adding brain volume loss to the modified Rio scoring system improves prediction of future disability progression: Analyses from fingolimod Phase III trials (P5.202). Neurology. 84(14_supplement). 1 indexed citations
17.
18.
19.
Anthony, Daniel C., et al.. (2014). Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model. Neuropharmacology. 79. 534–541. 17 indexed citations
20.
Fischer, Lutz, Martina Sterneck, Daniela Piani Meier, Bernhard Zöllner, & Xavier Rogiers. (2002). The use of antiviral monotherapy and combination therapy for patients with hepatitis B virus infection after liver transplantation. Transplantation Proceedings. 34(6). 2283–2284. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Junko Ishizeki Breakdown of academic impact, for papers by Volkmar Heidecke Breakdown of academic impact, for papers by Kedar Mahajan Breakdown of academic impact, for papers by J. Figols Breakdown of academic impact, for papers by Guive Sharifi Breakdown of academic impact, for papers by Uma Kundu Breakdown of academic impact, for papers by Ayala Pollack Breakdown of academic impact, for papers by Yongqiang Dai Breakdown of academic impact, for papers by Renata Simm Breakdown of academic impact, for papers by Rana Zabad
Rankless by CCL
2026